GFRA1-PBD demonstrated synthetic lethality with DDR deficiency, both in vitro in BRCA1-isogenic paired cells and in vivo in the CTG-0012 model (Supplementary Figure 5 and Figure 5B), suggesting enhanced sensitivity of tumor cells to a GFRA1 ADC despite low receptor density. Here, GFRA1 is linked to neoplasm.